Search Within

MSK Grad Students

  1. "Wungki Park"
Formats
  1. Meeting Abstract (53)
  2. Journal Article (34)
  3. Review (5)
  4. Correspondence (3)
  5. Editorial (3)
Groups
  1. CTCR Scholars (98)
  2. Center for Pancreatic Cancer Research (98)
  3. Department of Medicine (98)
  4. Gastrointestinal Oncology Service (98)
  5. Master of Science in Clinical and Translational Cancer Research (98)
  6. Solid Tumor Oncology Division (98)

More Groups

People
  1. Wungki Park (98)
  2. Eileen O'Reilly (72)
  3. Anna Varghese (37)
  4. Kenneth Yu (33)
  5. Joanne Chou (25)
  6. William Jarnagin (25)

More People

Years
  1. 2025 (7)
  2. 2024 (27)
  3. 2023 (18)
  4. 2022 (12)
  5. 2021 (11)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal for ImmunoTherapy of Cancer (9)
  3. Annals of Surgical Oncology (5)
  4. Annals of Oncology (4)
  5. JCO Precision Oncology (4)
  6. Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (39)
  2. Biomed Central Ltd (9)
  3. Oxford University Press (7)
  4. Springer (7)
  5. Elsevier Inc. (5)
  6. Nature Publishing Group (5)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers
    Meeting Abstract

    Balogun, F.; Altoe, M.; O'Connor, C.; Chowdhury, N.; Cercek, A.; Lee, C. K.; Foote, M. B.; Kim, D.; Maron, S. B.; Kim, D. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
    Journal Article

    Florou, V.; Floudas, C. S.; Maoz, A.; Naqash, A. R.; Norton, C.; Tan, A. C.; Sokol, E. S.; Frampton, G.; Soares, H. P.; Puri, S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Durable response after olaparib treatment for perihilar cholangiocarcinoma with germline BRCA2 mutation
    Journal Article

    Costa, B. A.; Tallón de Lara, P.; Park, W.; Keane, F.; Harding, J. J.; Khalil, D. N.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Pancreatic cancer: BRCA targeted therapy and beyond
    Review

    Keane, F.; O’Connor, C. A.; Park, W.; Seufferlein, T.; O’Reilly, E. M.
    Cancers (2023)

    Fulltext@MSK | Save
  • Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: Opportunity and challenge
    Journal Article

    Keane, F.; Bajwa, R.; Selenica, P.; Park, W.; Roehrl, M. H.; Reis-Filho, J. S.; Mandelker, D.; O’Reilly, E. M.
    npj Precision Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations
    Meeting Abstract

    Tolcher, A. W.; Park, W.; Wang, J. S.; Spira, A. I.; Janne, P. A.; Lee, H. J.; Gill, S.; LoRusso, P.; Herzberg, B.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save